Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Orelabrutinib（O） in Combination With Thiotepa（T） in Refractory and Relapsed Primary CNS Lymphoma： A Single-arm, Multicenter Phase Ib/II Study（OT）

NCT05021770 is registered in ClinicalTrials.gov with Huiqiang Huang as lead sponsor.

NCT NCT05021770
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05021770 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Orelabrutinib（O） in Combination With Thiotepa（T） in Refractory and Relapsed Primary CNS Lymphoma： A Single-arm, Multicenter Phase Ib/II Study（OT）
Lead sponsor
Huiqiang Huang
Phase
Phase 1/2
Overall status
Unknown status
Start date
December 31, 2021
Completion date
June 30, 2024
Enrollment
29 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non hodgkin lymphoma, pcnsl, refractory and relapsed primary cns lymphoma